Proteome Systems raises $10m through a private placement to institutional and professional investors

September 08, 2005

Proteome Systems announced it has completed a conditional private placement to institutional and professional investors raising approx $10 million at $0.30 per share

The proceeds will allow the Company to accelerate development of its TB test and undertake clinical development of its scavenger drugs for dermatological conditions

Proteome Systems (ASX: PXL) today announced that it will raise approximately $10million through the issue of up to 33,333,333 fully paid ordinary shares to institutional and professional investors in the UK, US and Australia at a price of $0.30c per share.

The placement is conditional upon shareholder approval, which the Company will seek at an extraordinary general meeting to be convened in October 2005, with notices to be sent to shareholders shortly.

The net proceeds of the placement after broker and selling fees will be approximately $9.75million. These funds will provide the Company with sufficient working capital to further develop opportunities in its Diagnostics & Therapeutics business which it believes provide the best prospects for significant near term commercial returns.

The Company will accelerate the development of its rapid diagnostic test for active tuberculosis. This will build on local and international support received by the Company for its TB test programme over the past year, including a $2million START grant from the Australian government and entry into a commercial partnership with the Geneva based Foundation for Innovative New Diagnostics to fast track the development of this TB test.

The placement will also allow the Company to commence the clinical development of one of its lead scavenger drug compounds as a topical treatment for a range of dermatological diseases.

Stephen Porges, CEO of Proteome Systems, said "With the recent developments in our Diagnostics and Therapeutics businesses, we saw this as an ideal time to bring new investors into the Company. The recent validation of our Diagnostics and Therapeutics businesses, through our relationship with the Foundation for Innovative New Diagnostics the US Government grant announced this week to develop our scavenger drug compounds lead us to be extremely positive about the new direction of the Company"

The new shares will be issued following an EGM scheduled for October 2005, if shareholder approval is obtained and will rank equally with the Company's ordinary shares. The Company will apply to the ASX for quotation of the shares following their issue.
-end-
Background on Proteome Systems:

Proteome Systems Discovery & Diagnostics business discovers protein biomarkers that have potential for use as diagnostics and therapeutic targets in the areas of respiratory disease, neurobiology & aging and cancer. With the recent acquisition of Eukarion Inc., the Discovery & Diagnostics business has a portfolio of drugs entering clinical development. Proteome Systems Technology business develops and commercialises innovative technology solutions to enable proteomics and glycomics research. These solutions include integrated instrument-based systems, consumables and bioinformatic software. Additional information about Proteome Systems can be found at http://www.proteomesystems.com.

For further information contact:
Stephen Porges
CEO, Proteome Systems Limited
Phone: 61-429-420-237

Research Australia

Related Investors Articles from Brightsurf:

Words matter: Revealing 'how' restaurateurs land investors online
Online crowdfunding is a multibillion dollar industry, but crafting a compelling pitch that stands out among thousands of projects and lands investors is challenging, especially in the restaurant industry.

Tendency to select targeted retirement fund ending in zero may impact wealth
New research shows that selecting a targeted retirement fund that ends in a zero could negatively impact your retirement savings.

Zero rates preferable to negative rates for investors' risk-taking -Ben-Gurion U study
In several lab experiments, the researchers demonstrated that a zero-interest rate policy has the strongest impact on individuals' investment decisions driving their decisions to borrow money and the percentage of risky assets in their portfolios.

Investors punish for social irresponsibility depending on proportion of company execs with law degrees
The extent to which investors punish firms for corporate social irresponsibility is associated with the proportion of top management executives in a firm who have a law degree, according to new research from the University of Notre Dame.

Social banks rely on their motivated investors
The main reason for the existence of social banks is to fund other social enterprises.

Wall Street investors react to climate change
Institutional investors are factoring climate risks into their investment decisions, according to a first-ever survey conducted by the McCombs School of Business at The University of Texas at Austin.

Tiny price gaps cost investors billions
New research shows that, millions of times each day, investors in the US stock market see different prices at the same moment -- and that these differing prices cost investors at least $2 billion dollars each year.

Air travel reduces local investment bias, benefits investors and firms, study shows
Easy access to air travel has not only flattened the world, it also has flattened the bias toward investing locally, according to new research from the University of Notre Dame.

Study finds companies may be wise to share cybersecurity efforts
Research finds that when one company experiences a cybersecurity breach, other companies in the same field also become less attractive to investors.

Study: Want more investors to your startup? Better make an impassioned pitch
The brains of potential investors are wired to pay closer attention to entrepreneurs who pitch with passion, according to new research from Case Western Reserve University.

Read More: Investors News and Investors Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.